Editas Medicine Stock Alpha and Beta Analysis
| EDIT Stock | USD 1.84 0.02 1.08% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Editas Medicine. It also helps investors analyze the systematic and unsystematic risks associated with investing in Editas Medicine over a specified time horizon. Remember, high Editas Medicine's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Editas Medicine's market risk premium analysis include:
Beta 2.15 | Alpha 0.24 | Risk 13.78 | Sharpe Ratio 0.0312 | Expected Return 0.43 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Editas |
Editas Medicine Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Editas Medicine market risk premium is the additional return an investor will receive from holding Editas Medicine long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Editas Medicine. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Editas Medicine's performance over market.| α | 0.24 | β | 2.15 |
Editas Medicine expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Editas Medicine's Buy-and-hold return. Our buy-and-hold chart shows how Editas Medicine performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Editas Medicine Market Price Analysis
Market price analysis indicators help investors to evaluate how Editas Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Editas Medicine shares will generate the highest return on investment. By understating and applying Editas Medicine stock market price indicators, traders can identify Editas Medicine position entry and exit signals to maximize returns.
Editas Medicine Return and Market Media
The median price of Editas Medicine for the period between Fri, Nov 29, 2024 and Thu, Feb 27, 2025 is 1.38 with a coefficient of variation of 28.34. The daily time series for the period is distributed with a sample standard deviation of 0.46, arithmetic mean of 1.61, and mean deviation of 0.39. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Hopfield Jessica of 45000 shares of Editas Medicine at 5.6415 subject to Rule 16b-3 | 11/29/2024 |
2 | Disposition of 541 shares by Mei Baisong of Editas Medicine at 2.0772 subject to Rule 16b-3 | 12/03/2024 |
3 | Brokerages downgrade gene editing company Editas to hold, shares slump 23 | 12/13/2024 |
4 | Editas Medicines SWOT analysis gene editing firm pivots strategy amid stock uncertainty | 12/18/2024 |
5 | Acquisition by Mei Baisong of 54000 shares of Editas Medicine at 8.72 subject to Rule 16b-3 | 12/19/2024 |
6 | Why Is Editas Medicine, Inc. Among the Top CRISPR Stocks to Invest In | 12/30/2024 |
7 | CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10 Major Market Players | 01/13/2025 |
8 | Acquisition by Scadden David of 25000 shares of Editas Medicine at 9.55 subject to Rule 16b-3 | 01/15/2025 |
9 | Brokers Offer Predictions for Editas Medicine FY2025 Earnings | 01/22/2025 |
10 | Editas Medicine, Inc. Short Interest Up 7.6 percent in January - MarketBeat | 02/07/2025 |
11 | Genome Engineering Market To Reach USD 30.9 Billion by 2032, Growing at CAGR 16.7 percent Agilent Technologies, Bluebird Bio, Boehringer Ingelheim | 02/12/2025 |
12 | PTC Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher | 02/20/2025 |
13 | Editas Medicine to Announce Fourth QuarterFull Year 2024 Financial Results and to Participate in Investor Conferences in March | 02/24/2025 |
14 | Mirum Pharmaceuticals, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/26/2025 |
About Editas Medicine Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Editas or other stocks. Alpha measures the amount that position in Editas Medicine has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Graham Number | 18.75 | 14.44 | 16.61 | 20.45 | Receivables Turnover | 3.83 | 7.67 | 8.82 | 8.38 |
Editas Medicine Upcoming Company Events
As portrayed in its financial statements, the presentation of Editas Medicine's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Editas Medicine's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Editas Medicine's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Editas Medicine. Please utilize our Beneish M Score to check the likelihood of Editas Medicine's management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Editas Medicine
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.